Maxim analyst Jason McCarthy lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $2 from $5 and keeps a Buy rating on the shares. The firm is positive on the company’s plans to meet with the FDA or the brilaroxazine program in Q4 to discuss the potential for an NDA submission, though its price target cut reflects its recent equity dilution, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals price target lowered to $3 from $7 at Roth Capital
- Reviva Pharmaceuticals price target lowered to $2 from $5 at Maxim
- Reviva Pharmaceuticals reports Q2 EPS (12c) vs. (26c) last year
- Reviva Pharmaceuticals Announces Public Offering Agreement
- Reviva Pharmaceuticals prices 20M shares at 50c in public offering